Last reviewed · How we verify
Treatment of bronchial asthma, transient or intermittent in nature, when oral therapy is not appropriate — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Ephedrine Hydrochloride 3 MG/ML | Ephedrine Hydrochloride 3 MG/ML | University Hospital, Ghent | Sympathomimetic amine; adrenergic agonist | α-adrenergic receptors (α1, α2) and β-adrenergic receptors (β1, β2); sympathetic nerve terminals |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- University Hospital, Ghent · 1 drug in Treatment of bronchial asthma, transient or intermittent in nature, when oral therapy is not appropriate
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Treatment of bronchial asthma, transient or intermittent in nature, when oral therapy is not appropriate:
- Treatment of bronchial asthma, transient or intermittent in nature, when oral therapy is not appropriate treatment updates — RSS
- Treatment of bronchial asthma, transient or intermittent in nature, when oral therapy is not appropriate treatment updates — Atom
- Treatment of bronchial asthma, transient or intermittent in nature, when oral therapy is not appropriate treatment updates — JSON
Cite this brief
Drug Landscape (2026). Treatment of bronchial asthma, transient or intermittent in nature, when oral therapy is not appropriate — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-bronchial-asthma-transient-or-intermittent-in-nature-when-oral-therapy-is-not-appropriate. Accessed 2026-06-10.
Related
- Treatment of bronchial asthma, transient or intermittent in nature, when oral therapy is not appropriate full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing